EUCTR2005-005506-23-PT进行中（未招募）不适用
A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys 180 µg plus Copegus 1000 or 1200 mg to the Currently Approved Combination of Pegasys 180 µg plus Copegus 800 mg in Interferon-naïve Patients with Chronic Hepatitis C Genotype 1 virus infection coinfected with human immunodeficiency virus (HIV-1).
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients >= 18 years of age
- •Serological evidence of CHC infection by an anti-HCV antibody test (current or historical)
- •Detectable plasma HCV-RNA (>600 IU/mL)
- •Evidence of HCV genotype 1 infection by molecular assay
- •Chronic liver disease consistent with CHC infection on a biopsy obtained within the past 18 months as judged by a central pathologist. Up to 20% of patients with cirrhosis or incomplete cirrhosis will be allowed to enter the trial
- •Child Pugh total score at screening must be equal to 5 for a patient with cirrhosis or bridging fibrosis/transition to cirrhosis to be enrolled into NV18209. The only exception would be an elevation in Child Pugh total score (of >= 6) secondary to total bilirubin as a consequence of a concomitant medication (e.g. atazanavir and indinavir) or a clinical condition (e.g. Gilbert's syndrome) that may cause hyperbilirubinemia. An elevation in Child Pugh total score (of >= 6) secondary to albumin, INR, ascites or hepatic encephalopathy will not be acceptable
- •Patients with cirrhosis or incomplete cirrhosis must have an abdominal ultrasound, CT scan, or MRI scan without evidence of hepatocellular carcinoma (within 2 months of randomization) and a serum alpha-fetoprotein (AFP) <100 ng/mL
- •Serological evidence of HIV-1 infection by HIV-1 antibody or detection of HIV-1 RNA
- •Clinically stable status of HIV-1 infection in the opinion of the investigator, ie, patients who are not expected to progress during the study
- •Patients with a CD4+ count >= 100 cells/µL
- •Patients with HIV disease who are receiving stable antiretroviral therapy (ART) or for whom antiretroviral therapy is not required.
- •Negative urine or blood pregnancy test result (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug.
- •Additionally, all males with female partners of childbearing potential and sexually active females of childbearing potential must be using two forms of effective contraception (combined) during treatment and during the 6 months after treatment end.
- •Willingness to give written informed consent and willingness to participate in and comply with the study requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of having received alpha IFNs, PEG-IFN, ribavirin (RBV), viramidine, levovirin or investigational HCV protease or polymerase inhibitors at any previous time. Any history of systemic antiviral therapy, with established or perceived activity against HCV, =< 3 months prior to the first dose of study medication
- •Infection with any HCV genotype other than genotype 1 or infection with a mixed genotype or with a genotype that can not be established as genotype 1, i.e. ndeterminant genotype
- •History or other evidence of decompensated liver disease or a Child-Pugh score >5.
- •Coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- •Positive test result at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab
- •History or other evidence of a medical condition associated with chronic liver disease other than HCV
- •Evidence of an active or suspected cancer or a history of malignancy where the risk of recurrence is >= 20% within 2 years. Patients with liver cirrhosis with a lesion suspicious for hepatic malignancy on the screening imaging study will be eligible only if the likelihood of carcinoma is =<10% following an appropriate evaluation
- •Active HIV-related opportunistic infection and/or malignancy requiring acute systemic therapy
- •Within 6 weeks of starting the study screening period, the use of colony stimulating factors , such as granulocyte colony stimulating factor (GCSF) or erythropoietin to elevate hematology parameters. (These factors may be used after treatment has commenced)
- •Absolute neutrophil count (ANC) <1500 cells/mm3, except for African-Americans whose ANC should not be <1200 cells/mm3
- •Platelet count <70,000 cells/mm3
- •Hemoglobin <11 g/dL in females or <12 g/dL in males or any patient with a aseline
- •increased risk for anemia (eg, thalassemia, sickle cell anemia, spherocytosis, history
- •of GI bleeding) or for whom anemia would be medically problematic.
- •Serum creatinine level >1.5 times the upper limit of normal at screening
- •History of severe psychiatric disease including psychosis and or depression, a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease
- •History of uncontrolled severe seizure disorder
- •History of immunologically mediated disease (eg, inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis (defined as affecting > 10% of the body, where the palm of one hand equals 1%, or if the hands and feet are affected), rheumatoid arthritis requiring more than intermittent nonsteroidal anti-inflammatory medications for management
- •History or other evidence of chronic pulmonary disease associated with functional limitation
- •History of significant cardiac disease that could be worsened by acute anemia (eg, NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). In addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (as may be seen with RBV therapy) would not be well-tolerated
- •Poorly controlled thyroid dysfunction
- •History or other ev
研究者
相似试验
尚未招募
1 期
A Study to Evaluate BW-00163 in Subjects with HypertensioHypertensionACTRN12622001430729ARGO BIOPHARMA AUSTRALIA PTY LTD48
终止
1 期
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Topical SM04755 Solution Following Topical Administration to Subjects with Mild to Moderate Plaque PsoriasisPlaque psoriasisACTRN12617001178336Samumed Pacific Pty Ltd13
已完成
1 期
Intranasal Adenoviral vector COVID-19 vaccine (BBV154) Phase 1 studyCTRI/2021/02/031295Bharat Biotech International Ltd
进行中（未招募）
不适用
Safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) in primary infant vaccination.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.MedDRA version: 13.1Level: PTClassification code 10043376Term: TetanusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: LLTClassification code 10018952Term: Haemophilus influenzae infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10034738Term: PertussisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10013023Term: DiphtheriaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10036012Term: PoliomyelitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-021569-58-FIGlaxoSmithKline Biologicals720
进行中（未招募）
3 期
A Phase III Study to check the Safety and efficacy of the PCV 13 Vaccine in Healthy Infants in India in prevention of Pneumococcal disease caused by Streptococcus pneumonia.CTRI/2022/11/047443G C Chemie Pharmie Ltd